

Assessment of Electrocardiographic P Wave Dispersion in Individuals with and without Psoriasis: A Cross-sectional Study

LAYA JAYARAJAN NAIR¹, SANDHYA SOMASEKHARAN NAIR²,
SURESH MUTHEZATHU KESAVADAS³, ANUJA ELIZABETH GEORGE⁴



ABSTRACT

Introduction: Psoriasis is a prevalent, long-lasting inflammatory skin condition characterised by various clinical manifestations and arising from the interaction of genetic, environmental, and immunological factors. It has been found to be associated with several medical conditions, such as hypertension, diabetes, Cardiovascular (CV) diseases, and metabolic syndrome.

Aim: To compare the Electrocardiographic P Wave Dispersion (PWD) in individuals with and without psoriasis and to correlate PWD with the Psoriasis Area Severity Index (PASI) score.

Materials and Methods: This was a hospital-based cross-sectional study comparing the electrocardiographic PWD in 30 patients with psoriasis to that of 30 age- and gender-matched subjects without psoriasis who attended Government Medical College, Trivandrum, Kerala, India, during a period of one year (February 2021 to January 2022). A structured questionnaire was used to record history and examination findings. A 12-lead Electrocardiogram (ECG) was performed on study participants from both groups in a supine position following 15 minutes of

rest. Categorical and quantitative variables were expressed as frequency (percentage) and mean \pm SD, respectively. The Karl Pearson test was used to find correlations. A p-value of ≤ 0.05 was considered statistically significant.

Results: Ten (33.3%) patients belonged to the age group of 41-50 years. The duration of the disease ranged from six months to 21 years. Seventeen (56.7%) patients had a PASI score between 10-20, and 5 (16.7%) patients had a PASI score of less than 10. The maximum value of the P wave and PWD was higher in the case group and was statistically significant ($p \leq 0.001$ and $p \leq 0.001$, respectively). A statistically significant correlation was found between the severity of psoriasis and PWD ($r=0.564$, $p \leq 0.001$) and between the duration of psoriasis and PWD ($r=0.372$, $p=0.04$) in this study.

Conclusion: PWD was found to be higher in psoriasis patients, with a significant correlation between PWD and both the severity and duration of the disease. Therefore, ECG should be considered as a screening test for Atrial Fibrillation (AF) in all psoriasis patients.

Keywords: Atrial fibrillation, Cardiovascular diseases, Psoriasis area severity index score

INTRODUCTION

Psoriasis is a chronic inflammatory skin disorder mediated by type 1 T helper cells and Th17 cells, affecting about 2-3% of the population [1,2]. It is associated with several medical conditions, the most common of which are CV diseases, hypertension, diabetes, and metabolic syndrome [3,4]. The association between psoriasis and CV diseases is only partially understood; however, inflammatory processes and oxidative stress are among the most frequently delineated pathogeneses [5].

Among CV diseases, accumulating evidence highlights the role of inflammation in the pathogenesis of AF, a known cause of increased morbidity and mortality [4,6]. The most common cardiac arrhythmia, AF, is linked to a higher risk of stroke, heart failure, coronary artery disease, and CV mortality [7,8].

Prolongation of PWD is an independent risk factor for the development of AF. PWD has been proposed as an electrocardiographic indicator of inhomogeneous and discontinuous atrial conduction during sinus rhythm in patients with paroxysmal AF [9].

The P wave in an Electrocardiogram (ECG) represents atrial depolarisation, with a normal duration ranging from 40 to 120 milliseconds (ms). PWD is the difference between the maximum and minimum P wave duration on a single 12-lead ECG, with a normal duration of 29 ± 9 ms [10].

Even though psoriasis patients are more likely to develop CV diseases [11], only a few previous studies have examined the effect of psoriasis on the cardiac conduction system and its correlation with AF [12-15]. The association between psoriasis and AF remains

unexplored in the South Indian population. To the best of the author's knowledge, no such study has been conducted in Kerala.

A better understanding of the association between psoriasis and AF will enable the early identification of susceptible patients through screening processes. Hence, the present study was conducted to compare the electrocardiographic PWD among individuals with and without psoriasis and to correlate PWD with the severity of the disease.

MATERIALS AND METHODS

A hospital-based cross-sectional study was conducted in the Department of Dermatology and Venereology at Government Medical College, Trivandrum, Kerala, India, from February 2021 to January 2022. The study received clearance from the Institutional Ethics Committee (HEC No. 02/12/2021/MCT). Participants were provided with an information sheet outlining the details and purpose of the study. The study included 30 patients with psoriasis as the case group and 30 age- and gender-matched subjects without psoriasis, who accompanied other patients (non-psoriasis cases) to the Dermatology Department, as the control group.

Inclusion criteria: All consenting clinically diagnosed patients with psoriasis aged 18 years and older, as well as, all consenting individuals without psoriasis in the same age group, were included in the study as cases and controls, respectively.

Exclusion criteria: Patients with known cases of CV disease, chronic obstructive pulmonary disease, chronic kidney disease, thyroid disorders, or those already on CV medications were excluded from

the study. Additionally, when recruiting controls, individuals with pre-existing CV disease and first-degree relatives of psoriasis patients were also excluded.

Sample size: Sample size calculation was done by using a formula: $N = (Z_{1-\alpha/2} + Z_{1-\beta})^2 (\sigma_1^2 + \sigma_2^2) / (\mu_1 - \mu_2)^2$

Let 'N' represent the sample size. In the case group, the Standard Deviation (SD) of PWD (σ_1) was 22.9, and the mean value of PWD (μ_1) is 67.4. In the control group, the SD of PWD (σ_2) was 19.6, and the mean value of PWD (μ_2) was 45.0. The value of $(Z_{1-\alpha/2} + Z_{1-\beta})^2$ was 10.49, with a β value of 90% [12]. By substituting these values, we find that $N=20$. Therefore, 30 individuals were selected from both the case and control groups for the study.

Study Procedure

A detailed history of demography and comorbidities was collected using a structured questionnaire. A general examination was conducted, during which vital signs, height, and weight were recorded, and Body Mass Index (BMI) was calculated. The morphology of lesions, their distribution, nail changes, and joint involvement were documented through a thorough dermatological examination, and the PASI score was calculated [2]. A systemic examination was performed to rule out any associated diseases. A 12-lead ECG was conducted on study participants from both groups in a supine position after 15 minutes of rest, using a BPL ECG machine (Cardiart 6108T single channel). ECG recordings were obtained at a paper speed of 50 mm/s and an amplitude of 20 mm/mV. The beginning of the P wave was defined as the point where the first atrial deflection crossed the isoelectric line, and the end of the P wave was defined as the point where the atrial deflection returned to the isoelectric line [10].

The P wave was assessed, and the maximum and minimum durations of the P wave were recorded in all 12 ECG leads. The difference between the maximum and minimum P wave durations was then calculated (PWD in milliseconds).

STATISTICAL ANALYSIS

The data were entered into Microsoft Excel sheets, and statistical analysis was performed using a trial version of the Statistical Package for the Social Sciences (SPSS) version 20.0. Categorical and quantitative variables were expressed as frequency (percentage) and mean \pm SD, respectively. The Karl Pearson test was used to find the correlation between the presence of psoriasis with both the severity of the condition and the duration of the disease. A p-value of ≤ 0.05 was considered statistically significant.

RESULTS

A total of 30 patients with psoriasis who met the inclusion criteria and 30 age- and gender-matched individuals without psoriasis were studied. The age of the patients ranged from 18 to 70 years. Most of the patients (10, 33.3%) were between the ages of 41 and 50, followed by those aged 51 to 60 (8, 26.7%), with a male-to-female ratio of 2.3:1. The mean age of onset was 39.5 ± 11.3 years. Ten patients (33.3%) had their disease onset between the ages of 31 and 40 and between 41 and 50 years [Table/Fig-1]. The mean duration of the disease was 5.07 ± 5.2 years, with a range from six months to 21 years [Table/Fig-2]. The mean PASI score was 16.6 ± 8.6 , with scores ranging from 8 to 36. The frequency distribution of the cases according to PASI score is given in [Table/Fig-3].

A comparison of demographic features is shown in [Table/Fig-4], in which the mean Diastolic Blood Pressure (DBP) of patients with psoriasis was 78.3 ± 4.6 mmHg, while in the group without psoriasis it was 75 ± 5.7 mmHg.


The triggering factors for psoriatic patients are presented in [Table/Fig-5]. The majority of the patients (22, 73.3%) had a history of infection, and two patients (6.7%) reported no aggravating factors

Age of onset (in years)	With Psoriasis, n (%)
18-30	6 (20)
>30-40	10 (33.3)
>40-50	10 (33.3)
>50-60	3 (10)
>60-70	1 (3.3)

[Table/Fig-1]: Age of onset. n=Number; %=Percentage.

Duration of disease (in years)	With Psoriasis, n (%)
<1	2 (6.7)
1-5	19 (63.3)
>5-10	5 (16.7)
>10	4 (13.3)

[Table/Fig-2]: Duration of disease. n=Number; %=Percentage.



[Table/Fig-3]: Psoriasis Area Severity Index (PASI) score (n, percentage).

Characteristics	With Psoriasis	Without Psoriasis	p-value
Age (mean \pm SD)	44.5 \pm 10.8	44.5 \pm 10.8	1.000
Gender	21 males, 9 females	21 males, 9 females	1.000
Current smoker	8 (26.7 %)	10 (33.3 %)	0.834
Current alcoholic	7 (23.3%)	10 (33.3%)	0.543
Height (in cm)	164.8 \pm 5.2	166.6 \pm 6.3	0.234
Weight (in kg)	65.7 \pm 6.4	66.6 \pm 6.9	0.628
BMI (kg/m ²)	24.2 \pm 1.8	23.9 \pm 1.8	0.473
SBP (mmHg)	125.1 \pm 10.8	123.5 \pm 10.7	0.551
DBP (mmHg)	78.3 \pm 4.6	75 \pm 5.7	0.016
Heart rate (bpm)	72.6 \pm 6.6	70.9 \pm 7.4	0.343

[Table/Fig-4]: Comparison of demographic findings between psoriatic patients and individuals without psoriasis. SD: Standard deviation; BMI: Body mass index; SBP: Systolic blood pressure in millimeters of mercury; DBP: Diastolic blood pressure in millimeters of mercury; bpm: beats per minute. A p-value < 0.05 is considered significant.

Triggering Factors	Frequency (percentage)
Infection and psychological stress	11 (36.7%)
Infection alone	11 (36.7%)
Psychological stress alone	6 (20%)
History of trauma	4 (13.3%)
No aggravating factors	2 (6.7%)

[Table/Fig-5]: Triggering factors in psoriatic patients.

[Table/Fig-5]. All patients had plaque lesions. Joint involvement was present in five patients (16.7%), and nail changes were observed in 28 patients (93.3%).

Among the 30 psoriatic patients, PWD was greater than 40 in 22 patients (73.3%), compared to 12 individuals (40%) without psoriasis. The difference in PWD between the groups was found to be statistically significant, with a p-value of less than 0.001 [Table/Fig-6].

PWD (ms)	With Psoriasis		Without Psoriasis	
	n	%	n	%
20-30	4	13.3	10	33.3
31-40	4	13.3	8	26.7
41-50	7	23.3	10	33.3
51-60	4	13.3	0	0.0
61-70	8	26.7	2	6.7
71-80	2	6.7	0	0.0
81-90	1	3.3	0	0.0
Mean±SD	56.0±16.2		42.0±11.1	

[Table/Fig-6]: Comparison of P Wave Dispersion (PWD), t=3.814, p<0.001. n=Number, %=Percentage, ms=milliseconds, SD=Standard deviation. p-value<0.05 considered as significant

The mean P max was significantly higher in psoriatic patients (108.3±14.16 ms) than in non-psoriatic individuals (98.3±13.4 ms), with a p-value ≤0.001 [Table/Fig-7]. The mean P-minimum was lower in psoriatic patients (52.3±12.8 ms) compared to non-psoriatic individuals (56.3±13.3 ms) [Table/Fig-8]. A statistically significant correlation was observed between the severity of psoriasis and electrocardiographic PWD (r=0.564, p-value≤0.001). A scatter diagram of electrocardiographic PWD and the PASI is shown in [Table/Fig-9].

P max (ms)	With Psoriasis		Without Psoriasis	
	n	%	n	%
61-80	3	10.0	9	30.0
81-100	11	36.6	14	46.7
101 -120	14	46.7	7	23.3
121-140	2	6.7	0	0.0
Mean±SD	108.3±14.16		98.3±13.4	

[Table/Fig-7]: Comparison of P wave maximum. P max=P wave maximum, t=3.34** p<0.001. n=Number, %=percentage, ms=milliseconds, SD=standard deviation. p-value<0.05 considered as significant.


P min (ms)	With Psoriasis		Without Psoriasis	
	n	%	n	%
20-30	2	6.7	2	6.7
31-40	7	23.3	5	16.7
41-50	12	40.0	7	23.3
51-60	0	0.0	4	13.3
61-70	9	30.0	12	40.0
Mean±SD	52.3±12.8		56.3±13.3	

[Table/Fig-8]: Comparison of P wave minimum. P min=P wave minimum, t=0.99, p=0.166. n=Number, %=percentage, ms=milliseconds, SD=standard deviation. p-value < 0.05 considered as significant.


Additionally, [Table/Fig-10] presents the value of Karl Pearson's coefficient of correlation between PASI and PWD. A statistically significant correlation was also observed between electrocardiographic PWD and the duration of the disease (r=0.372, p-value=0.04). A scatter diagram of electrocardiographic PWD and the duration of the disease is shown in [Table/Fig-11].

DISCUSSION


The present study included 30 patients with a clinical diagnosis of psoriasis and an equal number of age- and gender-matched individuals without psoriasis. The most common age group was 31-50 years, with a mean age of 44.5±10.8 years for



[Table/Fig-9]: Scatter diagram for Psoriasis Area Severity Index (PASI) Score (PASI) and Electrocardiographic P wave Dispersion (PWD), r (Karl Pearson's coefficient of correlation)=0.564**, p<0.001. p-value<0.05 considered as significant



[Table/Fig-10]: Heatmap of Karl Pearson's coefficient of correlation of PWD, PASI and DoD. PWD: P wave dispersion; PASI: Psoriasis area severity index score; DoD: Duration of disease



[Table/Fig-11]: Scatter diagram for Electrocardiographic P wave Dispersion and duration of disease, r (Karl Pearson's coefficient of correlation)=0.372, p=0.04. p-value<0.05 considered as significant.

the patients, which was comparable to most other studies on psoriasis [16,17]. This finding was discordant with that observed by Bacaksiz A et al., and Simsek H et al., (33.7±6.7 and 35.8±13 years, respectively) [12,18]. The majority of the patients in this study were men (70%), consistent with most previous studies [12,16-17].

The mean age at onset of the disease was 39.5±11.3 years, with a minimum age of onset of 19 years and a maximum of 62 years. This was discordant with the study by Bacaksiz A et al., (20.1±7.7 years) [12]. The mean duration of the disease in this study was 5.07±5.2 years, which was discordant with the findings of Bacaksiz A et al., (12.8 years) and Markuszkeski L et al., (17 years) [12,16]. In a recent publication by Aryanian Z et al., the mean duration recorded was 10±8 years [14]. In the present study, the minimum disease duration was 6 months and the maximum was 21 years. However, in the studies by Bacaksiz A et al., Aryanian Z et al., and Markuszkeski L et al., the duration of disease ranged from 3 to 26 years, two months to 40 years, and 1 to 37 years, respectively [12,14,16].

In the present study, 28 (93.3%) patients with psoriasis reported a history of infection and/or psychological distress as factors aggravating their condition. Most of them attributed financial constraints and concerns regarding the chronic nature of psoriasis as the cause of their stress. In a study by Park BS et al., the most common precipitating factor noted was mental stress [19]. The mean PASI score was 16.6±8.6, ranging from 8 to 36. This result was almost concordant with the study by Markuszkeski L et al., which reported a mean PASI of 13.4±8.8 [16]. However, it was discordant with the findings of Bacaksiz A et al., where the mean PASI was 3.5±3.7, ranging from 0.4 to 16.8 [12].

The interpretation of the ECG of the participants showed that the mean Heart Rate (HR) was 72.6±6.6 beats per minute in psoriatic patients and 70.9±7.4 beats per minute in participants without psoriasis. This result was consistent with a study from Iran by Aryanian Z et al., [14]. However, it was discordant with the findings of Bacaksiz A et al., which reported a mean HR of 80.5±9.9 beats per minute in patients with psoriasis and 83.1±11.5 beats per minute in individuals without psoriasis [12]. Additionally, a study from Iran found a median HR of 82 beats per minute in the psoriasis group and 84 in the control group [13]. In all these studies, the results were not statistically significant between the groups.

The mean P max was significantly higher in psoriatic patients (108.3±14.16 ms) than in non-psoriatic individuals (98.3±13.4 ms). A higher P max indicates an abnormality in atrial conduction in patients with psoriasis. This finding was similar to that of Bacaksiz A et al., where the mean P max was 112.6±22.7 ms in psoriatic patients and 93.0±12.8 ms in individuals without psoriasis [12]. However, a study from Turkey reported a median P max of 100 ms in the case group and 88 ms in the control group, while Aryanian Z et al., reported 78.67±13.89 ms in cases and 80.06±15.57 ms in controls [13,14]. In all these studies, the results were statistically significant.

The mean P-minimum was lower in psoriatic patients (52.3±12.8 ms) compared to non-psoriatic individuals (56.3±13.3 ms). No statistical association was found between the groups. This finding was similar to that of Bacaksiz A et al., where among 61 cases, the P-min was 42.2±12.5 ms in psoriatic patients and 47.4±14.3 ms in controls, with results that were not statistically significant [12]. However, in the study by Aryanian Z et al., a statistical difference between groups was noted (38.22±6.86 ms among cases and 50.67±10.94 ms in controls) [14].

PWD was found to be prolonged in psoriatic patients, and this difference was statistically significant with a p-value≤0.001, indicating an increased risk of developing AF in patients with psoriasis compared to individuals without psoriasis. The mean PWD was 56±16.2 ms in psoriatic patients and 42±11.1 ms in non-psoriatic

individuals, respectively. Studies by Bacaksiz A et al., Namazi N et al., and Aryanian Z et al., have reported similar findings [12-14].

A statistically significant correlation was observed between the severity of psoriasis and PWD (p-value≤0.001). As the severity of psoriasis increases, PWD also increases, leading to a higher chance of developing AF later in life. Comparable findings were reported in a case-control study by Bacaksiz A et al., and in a recent observational study by Kumar U et al., [12,15]. In contrast, a study from Iran by Namazi N et al., reported no association between the severity of psoriasis and PWD [13].

In the study, a significant correlation was also observed between the duration of the disease and PWD, with a p-value of 0.04. This indicates that the longer the duration of psoriasis, the greater the PWD, and the higher the chance of developing AF. Therefore, an earlier onset of the disease correlates with a higher PWD and an increased risk of developing AF later in life. However, studies conducted by Namazi N et al., and Simsek H et al., observed no correlation between the duration of psoriasis and the incidence of arrhythmia [13,18].

Limitation(s)

The major limitation of this study was its cross-sectional design. Data were collected at a single point in time, with no follow-ups; therefore, trends that may recur over time could not be studied.

CONCLUSION(S)

This study showed that patients with psoriasis vulgaris had higher PWD, indicating an increased risk of AF compared to those without psoriasis. Additionally, the study revealed a significant correlation between PWD and both the severity and duration of the disease. Therefore, ECG, which is a reliable, non-invasive, and feasible method, should be considered as part of the screening process for AF, particularly in patients with severe and long-standing psoriasis. Prospective studies will be needed to confirm the development of AF in patients with psoriasis.

REFERENCES

- Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: Cohort study using the General Practice Research Database. *Eur Heart J*. 2010;31(8):1000-06.
- Griffiths CEM, Barker J, Bleiker T, Chalmers R, Creamer D. *Rook's Textbook of Dermatology* 9th edition: John Wiley & Sons, Ltd; 2016:1133-219.
- Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. *Lancet*. 2021;397(10281):1301-15.
- Yildiz A, Ucmak D, Oylumlu M, Akkurt MZ, Yuksel M, Akil MA, et al. Assessment of atrial electromechanical delay and P-wave dispersion in patients with psoriasis. *Echocardiography*. 2014;31(9):1071-76.
- Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dyslipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. *Clin Chim Acta*. 2001;303(1-2):33-39.
- Chiu HY, Chang WL, Huang WF, Wen YW, Tsai YW, Tsai TF. Increased risk of arrhythmia in patients with psoriatic disease: A nationwide population-based matched cohort study. *J Am Acad Dermatol*. 2015;73(3):429-38.
- Tsang TSM, Miyasaka Y, Barnes ME, Gersh BJ. Epidemiological profile of atrial fibrillation: A contemporary perspective. *Prog Cardiovasc Dis*. 2005;48(1):01-08.
- Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Seward JB, et al. Coronary ischemic events after first atrial fibrillation: Risk and survival. *Am J Med*. 2007;120(4):357-63.
- Dilaveris PE, Gialafos EJ, Sideris SK, Theopistou AM, Andrikopoulos GK, Kyriakidis M, et al. Simple electrocardiographic markers for the prediction of paroxysmal idiopathic atrial fibrillation. *Am Heart J*. 1998; 135(5):733-38.
- Pérez-Riera AR, de Abreu LC, Barbosa-Barros R, Grindler J, Fernandes-Cardoso A, Baranchuk A, et al. P-wave dispersion: An update. *Indian Pacing Electrophysiol J*. 2016;16(4):126-33.
- Garshick MS, Ward NL, Krueger JG, Berger JS. Cardiovascular risk in patients with psoriasis: JACC review topic of the week. *J Am Coll Cardiol*. 2021;77(13):1670-80.
- Bacaksiz A, Erdogan E, Tasal A, Vatankulu MA, Kul S, Sevgili E, et al. Electrocardiographic P-wave characteristics in patients with psoriasis vulgaris. *Ups J Med Sci*. 2013;118(1):35-41.
- Namazi N, Helali M, Pishgahi M, Ketabi Y. Assessment of P-wave indices as atrial fibrillation predictors in psoriasis patients. *Iran J Dermatol*. 2017;20(4):113-17.
- Aryanian Z, Jafaripour I, Kohneshin E, Pourkia R, Hedayati Goudarzi MT, Tigrar Tabari S, et al. Echocardiographic and electrocardiographic assessments in patients with psoriasis. *Caspian J Intern Med*. 2021;12(2):162-66.

- [15] Kumar U, Agarwal M, Varma K. Study of P wave dispersion in patients of psoriasis: An observational study. *IP Indian Journal of Clinical and Experimental Dermatology*. 2023;9(2):66.
- [16] Markuszkeski L, Bissinger A, Janusz I, Narbutt J, Jedrzejowska AS, Zalewska A. Heart rate and arrhythmia in patients with psoriasis vulgaris. *Arch Med Res*. 2007;38(1):64-69.
- [17] Ahlehoff O, Gislason GH, Jorgensen CH, Lindhardsen J, Charlott M, Oleson JB, et al. Psoriasis and risk of atrial fibrillation and ischaemic stroke: A Danish Nationwide Cohort Study. *Eur Heart J*. 2012;33(16):2054-64.
- [18] Simsek H, Sahin, Akypol A, Akdag S, Ozkol HU, Gumrukcuoglu A, et al. Increased risk of atrial and ventricular arrhythmia in long-lasting psoriasis patients. *Scientific World Journal*. 2013;2013:901215.
- [19] Park BS, Youn JI. Factors influencing psoriasis: An analysis based upon the extent of involvement and clinical type. *J Dermatol*. 1998;25:97-102.

PARTICULARS OF CONTRIBUTORS:

1. Senior Resident, Department of Dermatology and Venereology, Government Medical College, Thiruvananthapuram, Trivandrum, Kerala, India.
2. Professor (CAP), Department of Dermatology and Venereology, Government Medical College, Thiruvananthapuram, Trivandrum, Kerala, India.
3. Former Professor, Department of General Medicine, Government Medical College, Thiruvananthapuram, Trivandrum, Kerala, India.
4. Professor, Department of Dermatology and Venereology, Government Medical College, Thiruvananthapuram, Trivandrum, Kerala, India.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Laya Jayarajan Nair,
Makeeriyam, Paliyerikoval, Karivellur P.O. Kannur, Payyanur-670521, Kerala, India.
E-mail: layajnair48@gmail.com

PLAGIARISM CHECKING METHODS: [Jain H et al.]

- Plagiarism X-checker: Jun 17, 2024
- Manual Googling: Jul 15, 2024
- iThenticate Software: Sep 25, 2024 (15%)

ETYMOLOGY: Author Origin**EMENDATIONS:** 8**AUTHOR DECLARATION:**

- Financial or Other Competing Interests: None
- Was Ethics Committee Approval obtained for this study? Yes
- Was informed consent obtained from the subjects involved in the study? Yes
- For any images presented appropriate consent has been obtained from the subjects. NA

Date of Submission: **Jun 12, 2024**Date of Peer Review: **Jul 16, 2024**Date of Acceptance: **Sep 26, 2024**Date of Publishing: **Nov 01, 2024**